First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

20260 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov Identifier: NCT03924986.

Good health and well-being

Published in: JAMA Oncology

Field-Weighted Citation Impact: 0.00